Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance
Taxis Pharmaceuticals2025-07-24T17:04:14-04:00Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.